Elon Musk’s brain-computer interface venture, Neuralink, is poised to launch a groundbreaking clinical trial in the United States this October. The trial will employ Neuralink’s innovative device to transform thoughts directly into text, offering a revolutionary communication avenue for individuals suffering from language impairments. According to media reports on September 19, the U.S. Food and Drug Administration (FDA) has granted Neuralink an Investigational Device Exemption (IDE), paving the way for the company to test devices that are not yet commercially available.